Comparing a new biologic to a standard drug for advanced colorectal cancer
Part of Cancer clinical trials.
This trial tests a new medication (HLX05-N) against a standard treatment (Erbitux) for people with metastatic colorectal cancer that has not been treated before. It aims to see if the new drug works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread (metastatic) or is locally advanced and cannot be removed by surgery, and it started in the left side of your colon or rectum.
- Your cancer has certain gene markers (KRAS and NRAS normal, and no BRAF V600E mutation).
- You have not had any previous treatment for your advanced colorectal cancer.
- Your weight is between 50 and 85 kg and your BMI is between 18.5 and 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, or just one of those drugs by itself, for people with advanced colorectal cancer that has spread. It aims to see if these treatments can shrink the cancer or help you live longer.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests two new investigational drugs combined with either another experimental drug or an approved immunotherapy for advanced colorectal cancer that has stopped responding to standard chemotherapy. The goal is to see if these combinations can shrink tumors or slow cancer growth more effectively, and what side effects they may cause.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
This trial tests a new antibody drug against a standard one, both combined with chemotherapy, for advanced colorectal cancer that has not spread before. It aims to see which is safer and more effective.
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.